Peptide Information
General Information of This Peptide
| Peptide ID |
PEP00079
|
|||||
|---|---|---|---|---|---|---|
| Peptide Name |
LNCaP-specific peptide
|
|||||
| Structure |
|
|||||
| Sequence |
KYLAYPDSVHIW
|
|||||
| Peptide Type |
Linear
|
|||||
| Receptor Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Receptor Info | ||||
| PDC Transmembrane Types | Cell targeting peptides (CTPs) | |||||
| Formula |
C73H102N16O18
|
|||||
| Isosmiles |
[H]NCCCC[C@H](N[H])C(=O)N[C@@H](Cc1ccc(O[H])cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O[H])cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO[H])C(=O)N[C@H](C(=O)N[C@@H](Cc1cn([H])cn1)C(=O)N[C@]([H])(C(=O)N[C@@H](Cc1cn([H])c2ccccc12)C(=O)O)[C@@H](C)CC)C(C)C
|
|||||
| InChI |
InChI=1S/C73H102N16O18/c1-8-40(6)61(71(104)85-56(73(106)107)31-44-34-77-50-16-10-9-14-48(44)50)88-67(100)53(32-45-35-76-37-78-45)83-70(103)60(39(4)5)87-68(101)57(36-90)86-66(99)54(33-59(93)94)82-69(102)58-17-13-27-89(58)72(105)55(30-43-20-24-47(92)25-21-43)84-62(95)41(7)79-64(97)51(28-38(2)3)81-65(98)52(29-42-18-22-46(91)23-19-42)80-63(96)49(75)15-11-12-26-74/h9-10,14,16,18-25,34-35,37-41,49,51-58,60-61,77,90-92H,8,11-13,15,17,26-33,36,74-75H2,1-7H3,(H,76,78)(H,79,97)(H,80,96)(H,81,98)(H,82,102)(H,83,103)(H,84,95)(H,85,104)(H,86,99)(H,87,101)(H,88,100)(H,93,94)(H,106,107)/t40-,41-,49-,51-,52-,53-,54-,55-,56-,57-,58-,60-,61-/m0/s1
|
|||||
| InChIKey |
LDCMKJGJHPLNKZ-DQBGLSEJSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1491.713
|
Polar area
|
543.11
|
||
|
Complexity
|
1490.7558
|
xlogp Value
|
-0.8122
|
|||
|
Heavy Count
|
107
|
Rot Bonds
|
47
|
|||
|
Hbond acc
|
19
|
Hbond Donor
|
19
|
|||
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
KYL-TGX [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Prostate cancer | ||||
| Efficacy Data | Inhinition rate |
14.93 µM
|
|||
| Administration Time | 72 h | ||||
| In Vitro Model | Prostate carcinoma | LNCaP C4-2 cell | CVCL_4782 | ||
| Half life period | 4 h | ||||
References